Table 4 Ongoing Cardiovascular Outcome Trials with SGLT2 inhibitors
SGLT2 Inhibitor | Trial Name; Clinical Trial Identifier | Primary Outcome Measure | Patient Populationa | Final Results |
|---|---|---|---|---|
Dapagliflozin | Dapagliflozin Effect on Cardiovascular Events. [DECLARE TIMI 58]; [66] NCT 01730534 | CV Death, non-fatal MI, non-fatal ischaemic stroke | N = 17,276 10 mg vs placebo HbA1C range not specified Age ≥ 40 years High CV risk | 2019 [Estimated] |
Canagliflozin | Canagliflozin Cardiovascular Assessment Study. CANVAS]; [67] NCT 01032629 | CV Death, non-fatal MI, non-fatal ishaemic stroke | N = 4422 100 mg/300 mg vs placebo HbA1C 7–10.5% Age ≥ 30 years High CV risk | June 2017 |
Canagliflozin | Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants with Diabetic Nephropathy [CREDENCE] [68]; NCT 02065791 | Time to first occurrence of an event in the primary composite of endpoint of ESKD, doubling of serum creatinine, renal or CV death. | N = 4200 100 mg vs placebo HbA1c 6.5–12% Age > 30 years GFR ≥ 30 to < 90 ml/min | June 2019 |